Puma Biotechnology(US:PBYI)2025-08-07 20:30Financial Performance - Puma Biotechnology reported net NERLYNX revenue of $49.2 million in Q2'25, an increase of approximately 11% compared to $44.4 million in Q2'24[6, 7, 9] - The company also saw an increase of about 14% in net revenue from Q1'25 ($43.1 million) to Q2'25 ($49.2 million)[9, 10] - Inventory change improved from -$2.3 million in Q2'24 to -$1.3 million in Q2'25[8] - Inventory change improved from -$4.7 million in Q1'25 to -$1.3 million in Q2'25[11] Sales Volume - Puma Biotechnology sold 2,608 ex-factory bottles of NERLYNX in Q2'25[12] - This represents an approximate 4% increase compared to the 2,515 bottles sold in Q2'24[16] - There was also an approximate 12% increase in bottles sold from Q1'25 (2,338 bottles) to Q2'25 (2,608 bottles)[14, 16] - Inventory change in bottles improved from -132 in Q2'24 to -72 in Q2'25[13] - Inventory change in bottles improved from -250 in Q1'25 to -72 in Q2'25[15] Dosage Trends - Approximately 71% of patients in Q2'25 started NERLYNX at a reduced dose (fewer than 6 pills per day)[17] Global Expansion - NERLYNX has received regulatory approvals and been commercially launched in various regions through partnerships, including Australia/SE Asia, Israel, Canada, Latin America, Europe, Greater China, Middle East, North and West Africa, South Africa, Turkey, and South Korea[22]